海马保护与靶区覆盖:3至10个脑转移瘤的四种立体定向放疗平台比较
本研究评估了四种立体定向放疗平台治疗3至10个脑转移瘤时海马剂量与靶区覆盖,发现即使SRS海马也可接受相当剂量,但将海马勾画为危及器官后几乎所有情况均可实现保护且不影响靶区覆盖。
要点
- 无海马保护时海马Dmax中位数在四种平台间差异显著(P < .0001)。
- 海马保护后多数计划无需修改,仅少数需重新计划。
- 海马保护可行且不损害靶区覆盖与适形性。
核心结论
- 即使采用SRS,海马仍可接受相当剂量,但将海马勾画为危及器官后几乎所有情况均可实现保护且不损害靶区覆盖。
研究设计与样本
- 回顾性研究,选取10例连续患者共14次治疗,针对3至10个脑转移瘤,分别用Gamma Knife、单等中心VMAT、CyberKnife和TomoTherapy进行计划比较。
主要发现
- 每计划中位转移瘤数为6个,平均总肿瘤体积为7.32 mL。
- 无海马保护时海马Dmax中位数分别为Gamma Knife 1.65 Gy、VMAT 9.81 Gy、CyberKnife 4.38 Gy、TomoTherapy 5.46 Gy(P < .0001)。
- 14个计划中,Gamma Knife和CyberKnife各3个需重新计划,VMAT 13个、TomoTherapy 8个需重新计划。
- 当肿瘤毗邻海马时,所有平台均有1个计划无法满足海马约束。
- 平均V12(与症状性放射性坏死相关)分别为Gamma Knife 23.57 mL、VMAT 76.77 mL、CyberKnife 40.86 mL、TomoTherapy 104.06 mL(P = .01)。
关键数值与推荐
- 计划目标为无海马保护时PTV覆盖V100 ≥95%。
- 海马约束为单次分割海马Dmax <6.6 Gy且受照≤4.5 Gy的海马体积<40%。
临床怎么用
- 对多发性脑转移瘤行SRS时应考虑将海马勾画为危及器官并施加保护约束。
- 海马保护在多数情况下可行且不影响靶区覆盖与适形性。
局限性
- 样本量较小(10例患者14次治疗),为单中心回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our purpose was to evaluate hippocampal doses and target volume coverage with and without hippocampal sparing when treating multiple brain metastases using various stereotactic radiosurgery (SRS) platforms. METHODS AND MATERIALS: We selected 10 consecutive patients with 14 separate treatments who had been treated in our department for 3 to 10 brain metastases and added hippocampal avoidance contours. All 14 treatments were planned with GammaPlan for Gamma Knife, Eclipse for single isocenter volumetric modulated arc therapy (VMAT), TomoTherapy Treatment Planning System (TPS) for TomoTherapy, and MultiPlan for CyberKnife. Initial planning was performed with the goal of planning target volume coverage of V100 ≥95% without hippocampal avoidance. If the maximum hippocampal point dose (Dmax) was <6.6 Gy in a single fraction and <40% of the hippocampi received ≤4.5 Gy, no second plan was performed. If either constraint was not met, replanning was performed with these constraints. RESULTS: There was a median of 6 metastases per plan, with an average total tumor volume of 7.32 mL per plan. The median hippocampal Dmax (in Gy) without sparing averaged 1.65, 9.81, 4.38, and 5.46, respectively (P < .0001). Of 14 plans, 3 Gamma Knife and CyberKnife plans required replanning, whereas 13 VMAT and 8 TomoTherapy plans required replanning. The hippocampal constraints were not achievable in 1 plan on any platform when the tumor was bordering the hippocampus. The mean volume of brain receiving 12 Gy (in mL), which has been associated with symptomatic radionecrosis, was 23.57 with Gamma Knife, 76.77 with VMAT, 40.86 with CyberKnife, and 104.06 with TomoTherapy (P = .01). The overall average conformity indices for all plans ranged from 0.36 to 0.52. CONCLUSIONS: Even with SRS, the hippocampi can receive a considerable dose; however, if the hippocampi are outlined as organs of risk, sparing these structures is feasible in nearly all situations with all 4 platforms, without detriment to target coverage, and should be considered in all patients undergoing SRS for multiple brain metastases. SUMMARY: Hippocampi play an important role in memory, and sparing of these structures in whole brain radiation can improve neurocognitive outcomes. The hippocampi are not routinely spared when using stereotactic radiosurgery. We evaluated the incidental dose to the hippocampi when treating multiple brain metastases and sought to examine if hippocampal sparing is feasible without detriment to target coverage. We found that hippocampal sparing is possible without affecting coverage or conformality in most cases across treatment platforms.
引用
- Zhang I, Antone J, Li J, et al. Hippocampal-sparing and target volume coverage in treating 3 to 10 brain metastases: A comparison of Gamma Knife, single-isocenter VMAT, CyberKnife, and TomoTherapy stereotactic radiosurgery. Pract Radiat Oncol. 2017. PMID: 28477798. doi:10.1016/j.prro.2017.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。